Condition: Amyotrophic Lateral Sclerosis · Sponsor: Rapa Therapeutics LLC
RAPA-501-ALS is a phase 2/3 expansion cohort study of RAPA-501 autologous hybrid TREG/Th2 cells in patients living with amyotrophic lateral sclerosis (pwALS).
This description comes directly from the study's public registry record.
Daniel Fowler, M.D. Chief Medical Officer, RAPA Therapeutics, LLC · (301) 518-3104 · dan@rapatherapeutics.com
Jennifer Sunga Regulatory Affairs Associate, RAPA Therapeutics, LLC · jsunga@rapatherapeutics.com
Always discuss trial participation with your own doctor first.
| Massachusetts General Hospital | Boston, Massachusetts, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04220190